ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XNCR Xencor Inc

22.42
0.00 (0.00%)
Pre Market
Last Updated: 08:07:50
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1
Bid Price 20.00
Ask Price 24.54
News -
Day High

Low
16.49

52 Week Range

High
30.21

Day Low
Company Name Stock Ticker Symbol Market Type
Xencor Inc XNCR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 22.42 08:07:50
Open Price Low Price High Price Close Price Prev Close
22.42
Trades Volume Avg Volume 52 Week Range
1 1 - 16.49 - 30.21
Last Trade Time Type Quantity Stock Price Currency
08:18:35 1 $ 22.42 USD

Xencor Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.37B 61.12M - 168.34M -126.09M -2.06 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Xencor News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No XNCR Message Board. Create One! See More Posts on XNCR Message Board See More Message Board Posts

Historical XNCR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week22.8123.5221.3422.25417,321-0.39-1.71%
1 Month23.4024.4521.3423.03767,815-0.98-4.19%
3 Months22.0626.8418.2621.97726,5220.361.63%
6 Months20.5726.8416.4920.90601,7751.858.99%
1 Year27.9730.2116.4922.30452,278-5.55-19.84%
3 Years41.6745.36516.4927.35354,139-19.25-46.20%
5 Years32.0458.34516.4931.14354,607-9.62-30.02%

Xencor Description

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Your Recent History

Delayed Upgrade Clock